Literature DB >> 6713775

Isosorbide 5-mononitrate kinetics.

R M Major, T Taylor, L F Chasseaud, A Darragh, R F Lambe.   

Abstract

The kinetics of isosorbide 5-mononitrate (5-ISMN) were studied in 12 healthy subjects after intravenous infusion and oral doses of 20 mg. Kinetic parameters calculated by model-independent methods or by assumption of a one-compartment open model were in good agreement. Mean (+/- SD) systemic clearance of 5-ISMN was 127 +/- 21 ml/min, volume of distribution was 48.5 +/- 6.1 l, t 1/2 was 4.4 +/- 0.5 hr, and mean residence time was 6.2 +/- 0.7 hr. At the end of intravenous infusion of 5-ISMN at a rate of 8 mg/hr for 2.5 hr, mean plasma drug concentrations reached 356 +/- 39 ng/ml. Oral doses of 5-ISMN were essentially completely absorbed (93% +/- 13% systemic availability), and mean peak plasma drug concentrations of 388 +/- 70 ng/ml occurred at 0.83 +/- 0.46 hr. Mean absorption t 1/2 was 19 +/- 12 min. Unlike other vasodilator organic nitrates in clinical use, 5-ISMN is notable for its relatively long t 1/2, essentially complete oral absorption, lack of active metabolites, and low intersubject variability in kinetics.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6713775     DOI: 10.1038/clpt.1984.90

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure.

Authors:  A Meissner; S Petersenn; H T Heidemann; U Osterkamp; R Simon; H M Schulte
Journal:  Klin Wochenschr       Date:  1991-03-18

Review 2.  Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.

Authors:  Xianhua Cao; Seth T Gibbs; Lanyan Fang; Heather A Miller; Christopher P Landowski; Ho-Chul Shin; Hans Lennernas; Yanqiang Zhong; Gordon L Amidon; Lawrence X Yu; Duxin Sun
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

Review 3.  Pharmacokinetics of various preparations of organic nitrates.

Authors:  J P Kampmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 4.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Glyceryl-1-nitrate pharmacokinetics in healthy volunteers.

Authors:  H Laufen; M Leitold
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

6.  Pharmacokinetics of oral glycerol-1-nitrate.

Authors:  H Laufen; M Leitold; R A Yeates
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis.

Authors:  J Evers; R Bonn; A Boertz; W Cawello; V Luckow; M Fey; F Aboudan; H A Dickmans
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Pharmacokinetics of isosorbide-5-nitrate in renal failure.

Authors:  J Evers; B Krakamp; W Klimkait; H A Dickmans; J Maddock; V Luckow; W Cawello; M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates.

Authors:  U Thadani; T Whitsett
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

10.  Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate.

Authors:  Ingelise Christiansen; Helle K Iversen; Jes Olesen; Peer Tfelt-Hansen
Journal:  J Headache Pain       Date:  2008-06-03       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.